Æterna Zentaris, Inc.
AEterna Zentaris, Inc. engages in the development of novel treatments in oncology and endocrinology, which currently investigating treatments for various unmet medical needs. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.